company background image
ATHA

Athira PharmaNasdaqGS:ATHA Stock Report

Market Cap

US$366.6m

7D

0.4%

1Y

-40.9%

Updated

27 Sep, 2021

Data

Company Financials +
ATHA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ATHA Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation.

Price History & Performance

Summary of all time highs, changes and price drops for Athira Pharma
Historical stock prices
Current Share PriceUS$9.83
52 Week HighUS$8.88
52 Week LowUS$34.79
Beta0
1 Month Change-8.64%
3 Month Change-5.48%
1 Year Change-40.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-42.55%

Recent News & Updates

Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.

Shareholder Returns

ATHAUS PharmaceuticalsUS Market
7D0.4%0.5%0.1%
1Y-40.9%14.3%35.3%

Return vs Industry: ATHA underperformed the US Pharmaceuticals industry which returned 14.3% over the past year.

Return vs Market: ATHA underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is ATHA's price volatile compared to industry and market?
ATHA volatility
ATHA Beta0
Industry Beta0.64
Market Beta1

Stable Share Price: ATHA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ATHA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201121Leen Kawashttps://www.athira.com

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer’s disease, as well as in clinical development for Parkinson’s disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy.

Athira Pharma Fundamentals Summary

How do Athira Pharma's earnings and revenue compare to its market cap?
ATHA fundamental statistics
Market CapUS$366.62m
Earnings (TTM)-US$39.03m
Revenue (TTM)n/a

0x

P/S Ratio

-9.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATHA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$39.03m
Earnings-US$39.03m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.05
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ATHA perform over the long term?

See historical performance and comparison

Valuation

Is Athira Pharma undervalued compared to its fair value and its price relative to the market?

1.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATHA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATHA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATHA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ATHA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATHA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATHA is good value based on its PB Ratio (1x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Athira Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-58.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATHA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATHA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATHA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATHA is forecast to have no revenue next year.

High Growth Revenue: ATHA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATHA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Athira Pharma performed over the past 5 years?

-519.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ATHA is currently unprofitable.

Growing Profit Margin: ATHA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ATHA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ATHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: ATHA has a negative Return on Equity (-11.12%), as it is currently unprofitable.


Financial Health

How is Athira Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ATHA's short term assets ($290.5M) exceed its short term liabilities ($7.6M).

Long Term Liabilities: ATHA's short term assets ($290.5M) exceed its long term liabilities ($1.8M).


Debt to Equity History and Analysis

Debt Level: ATHA is debt free.

Reducing Debt: ATHA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATHA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ATHA has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 91.2% each year.


Dividend

What is Athira Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATHA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATHA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATHA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Leen Kawas (35 yo)

7.67yrs

Tenure

US$1,349,042

Compensation

Dr. Leen Kawas, Ph D., serves as Chief Executive Officer and Director at Athira Pharma, Inc. (former name, M3 Biotechnology, Inc.) since January 2014 and serves as its President. Dr. Kawas served as Vice P...


CEO Compensation Analysis

Compensation vs Market: Leen's total compensation ($USD1.35M) is about average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Leen's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ATHA's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: ATHA's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.


Top Shareholders

Company Information

Athira Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Athira Pharma, Inc.
  • Ticker: ATHA
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$366.619m
  • Shares outstanding: 37.30m
  • Website: https://www.athira.com

Number of Employees


Location

  • Athira Pharma, Inc.
  • 18706 North Creek Parkway
  • Suite 104
  • Bothell
  • Washington
  • 98011-2141
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 23:06
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.